Related Experiment Videos
[Meningitis caused by Candida in a premature infant]
Boletin Medico Del Hospital Infantil De Mexico
|March 1, 1979
Summary
This case study details treating Candida meningitis in a premature infant with amphotericin B. While effective, intraventricular administration led to complications, highlighting treatment challenges in neonates.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pediatric Neurology
Background:
- Candida meningitis is a serious infection in premature infants, often associated with high mortality and neurological sequelae.
- Standard treatment involves systemic antifungal therapy, but achieving adequate cerebrospinal fluid (CSF) drug concentrations can be challenging.
- Intraventricular administration of antifungals is sometimes considered for refractory or severe cases.
Observation:
- A premature infant diagnosed with Candida meningitis received intravenous amphotericin B for 41 days.
- The treatment regimen included a 21-day course of intraventricular amphotericin B.
- Purulent meningitis developed as a complication during the intraventricular therapy phase.
Findings:
- CSF cultures turned negative within 5 days of initiating intravenous amphotericin B therapy.
- Despite initial microbiological clearance, the infant exhibited developmental delays, with a mental age of 3 months at 7 months chronological age.
- This case represents one of the few documented instances of intraventricular amphotericin B use in a premature infant.
Implications:
- The study underscores the complex management of invasive fungal infections in extremely vulnerable neonates.
- While effective in sterilizing CSF, intraventricular amphotericin B carries risks of neurological complications, necessitating careful monitoring.
- Further research into optimized dosing and administration strategies for neonatal Candida meningitis is warranted to improve outcomes.